Dongxin Jiang
Chuheng Wang
Yao Zhao
Yunqian Li- Department of Neurosurgery, The First Hospital of Jilin University, Changchun, China
Glioblastoma (GBM) is a highly aggressive brain tumor characterized by metabolic plasticity that fuels growth, therapy resistance, and immune evasion. Among its reprogrammed pathways, serine and lipid metabolism play central roles. The serine synthesis pathway (SSP)—via PHGDH, PSAT1, and SHMT2—supports nucleotide biosynthesis, redox balance, and epigenetic regulation, especially under hypoxic and nutrient-deprived conditions. Meanwhile, fatty acid flux, FABP7-mediated PUFA transport, and cholesterol uptake reshape the tumor microenvironment, sustain glioma stemness, and promote immune suppression. Key lipid enzymes and ferroptosis regulators such as MAGL, ACSL4, and xCT modulate tumor survival and therapy response. GBM cells also exhibit high reliance on exogenous cholesterol, with dysregulation of LXR–SREBP pathways and mevalonate flux contributing to autophagy and proliferation. Therapeutic strategies targeting metabolic vulnerabilities—including SSP blockade, cholesterol homeostasis disruption, and ferroptosis induction—show synergistic effects with conventional agents like temozolomide. This review highlights the intertwined metabolic circuits in GBM and explores their translational potential as targets for precision therapy.
1 Introduction
Glioblastoma (GBM) is the most aggressive and lethal primary malignancy of the central nervous system, characterized by diffuse infiltration, rapid proliferation, and pronounced therapeutic resistance (1, 2). While traditional studies have focused on oncogenes and signaling pathways, recent evidence positions metabolic reprogramming as a key driver of glioma pathogenesis, enabling adaptation to hypoxia, nutrient scarcity, and immunologic stress (3, 4). Among the diverse metabolic networks altered in GBM, serine and lipid metabolism emerge as closely intertwined hubs that collectively support tumor progression (5–8). The serine synthesis pathway (SSP)—via enzymes such as phosphoglycerate dehydrogenase (PHGDH), phosphoserine aminotransferase 1 (PSAT1), and serine hydroxy methyltransferase (SHMT2)—fuels nucleotide synthesis, NADPH generation, and one-carbon metabolism (9–11). In parallel, lipid metabolic rewiring, encompassing fatty acid elongation, desaturation, and cholesterol trafficking, provides the structural and energetic scaffolding for membrane formation, signal transduction, and immune modulation (12).
Importantly, serine and lipid metabolism are not independent circuits; rather, they converge at multiple regulatory and functional levels (13). For example, SSP-derived NADPH and S-adenosylmethionine (SAM) are indispensable for fatty acid desaturation and phospholipid methylation, while acetyl-CoA and folate intermediates link glycolysis, serine, and lipogenic flux (14). These integrated pathways are co-regulated by stress-adaptive transcription factors, including ATF4 and HIF-1α, and cooperate to maintain glioma stemness, redox homeostasis, and resistance to ferroptosis and chemotherapy (15, 16). Given the rising therapeutic interest in both SSP inhibitors (PHGDH, SHMT2) and lipid metabolism modulators (SCD1, FASN, LXR agonists), a comprehensive understanding of their metabolic and immunological crosstalk is urgently needed (6, 9, 10, 17). This review aims to synthesize current insights into serine–lipid metabolic integration in GBM, identify key regulatory nodes, and explore translational implications for precision therapy.
2 Roles of fatty acid metabolism in glioblastoma
2.1 Fatty acid metabolism remodels the tumor microenvironment
Fatty acids serve dual roles as substrates for β−oxidation and as structural constituents of phospholipids, glycolipids and cholesterol (18, 19). Critically, they also act as precursors for lipid mediators including eicosanoids and lysophosphatidic acid; dysregulated production of these molecules activates inflammatory signaling and drives GBM progression via RAS/PI3K/RHO pathways (20, 21). The GBM microenvironment, composed of neoplastic, stromal and immune cells such as tumour−associated macrophages (TAMs), is metabolically remodeled by fatty acid fluxes (22). Therapy resistance in GBM arises largely from glioblastoma stem cells (GSCs) (23, 24). TAMs promote tumour evolution through the ARS2–MAGL axis, wherein MAGL overexpression releases free fatty acids from monoacylglycerols, thereby fueling GSC self−renewal and prostaglandin E2 (PGE2) synthesis (25). PGE2 polarizes TAMs toward an immunosuppressive phenotype, characterized by impaired antigen presentation, increased secretion of IL−10 and TGF−β, and extracellular matrix remodelling (26, 27). These immunosuppressive TAMs in turn reinforce GSC stemness, invasion and neovascularization (28–30). By contrast, immunostimulatory TAMs—which exhibit elevated pro−inflammatory cytokine production, antigen−presenting capacity and cytotoxic activity—are linked to anti−tumour immunity (31). PGE2 further amplifies GSC self−renewal via pLRP6/β−catenin (Wnt) signaling, an effect reversible by the selective MAGL inhibitor JZL184 (25). Hypoxic niches, a hallmark of GBM, enhance Ras−dependent uptake of exogenous fatty acids. Under these conditions, stearoyl−CoA desaturase 1 (SCD1) sustains the oleic/stearic acid balance essential for membrane fluidity and cellular integrity (32). Suppression of glioma−enriched Ras−GRF1 induces apoptosis through the H−Ras/ERK cascade, highlighting its therapeutic potential (33, 34).
2.2 Fatty acid–binding proteins and other regulators in GBM
Fatty acid–binding proteins (FABPs) coordinate the intracellular trafficking of polyunsaturated fatty acids (PUFAs). Among these, FABP7 is highly expressed in astrocytes and neural progenitors (35, 36) and is upregulated in gliomas, where it exerts compartment-specific effects on tumor progression (37, 38). Cytoplasmic FABP7 complexes with arachidonic acid (AA) to enhance COX−2−dependent prostaglandin production, promoting tumor motility and metastasis. In contrast, nuclear FABP7 binds docosahexaenoic acid (DHA) and activates PPARγ signaling, which restrains invasion (39). Nuclear FABP7 also upregulates ATP−citrate lyase, supplying acetyl−CoA for the TCA cycle and de novo lipogenesis to sustain glioma bioenergetics. Epigenetically, FABP7 drives histone H3K27 acetylation at the caveolin−1 promoter, enhancing its transcription and facilitating lipid remodeling during gliomagenesis (40). In glioma stem cells, super−enhancer−driven expression of ELOVL2 enriches PUFA−containing phospholipids, increasing membrane fluidity and amplifying EGFR signaling to promote growth and therapy resistance (41). Ferroptosis, an iron−dependent cell death triggered by lipid peroxidation, represents a promising therapeutic avenue in GBM (42). Pseudomonic acid B induces ferroptosis by upregulating Nox4 and inhibiting the cystine/glutamate antiporter SLC7A11 (xCT). xCT knockdown similarly sensitizes cells to ferroptosis and synergizes with temozolomide (43, 44). The enzyme ACSL4 facilitates incorporation of PUFAs into phospholipids, thereby generating substrates for lipid peroxidation (45). ACSL4 overexpression further suppresses GPx4 activity, amplifying oxidative stress and ferroptotic cell death (46) (Figure 1).
Figure 1. Serine and lipid networks in glioblastoma.
2.3 Cholesterol metabolism in GBM
Cholesterol, a critical determinant of membrane integrity, is synthesized de novo through the mevalonate pathway, with 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase functioning as the key regulatory enzyme. Acetyl-CoA serves as the initial substrate, leading sequentially to HMG-CoA, mevalonate, and farnesyl pyrophosphate—a central precursor for cholesterol as well as for ubiquinone, heme A, and protein prenylation (47, 48). Within the central nervous system (CNS), which harbors approximately 20–25% of total body cholesterol, neural cells rely predominantly on local synthesis due to the impermeability of the blood–brain barrier to circulating lipoproteins; astrocytes are the principal producers (49). Newly synthesized cholesterol is packaged into ApoE-containing low-density lipoprotein (LDL)-like particles, internalized via LDL receptors (LDLR), and hydrolyzed within lysosomes. Additionally, astrocytes export cholesterol to neurons through ApoE-rich HDL-like particles in a process mediated by ABCA1 and ABCG1 transporters (50).
3 Cholesterol homeostasis and lipid raft signaling in GBM
3.1 Sterol regulatory element-binding proteins and liver X receptors
Cholesterol homeostasis in GBM is primarily regulated through the counterbalanced activities of SREBPs and liver X receptors (LXRs) (51). SREBP-2, in particular, directs cholesterol synthesis and uptake, whereas SREBP-1 isoforms modulate fatty acid metabolism (52). Oncogenic pathways involving mutant p53 and Akt enhance SREBP-2 activity, thereby activating Ras, RhoA (53), and YAP/TAZ signaling, which amplifies cholesterol production (54). The hypoxic and acidotic tumour microenvironment further stimulates nuclear translocation of SREBP-2 via HIF-1α and ACSS2, preserving acetyl-CoA levels to support autophagy and tumor growth (52, 55). Low-grade gliomas display elevated expression of cholesterol-related genes, implying that metabolic reprogramming may precede malignant transformation (56). LXRs counterbalance cholesterol accumulation by promoting efflux through ABCA1/ABCG1 and limiting LDLR-mediated import via induction of the E3 ligase IDOL (57). LXRα/β form obligate heterodimers with retinoid X receptors (RXRs) to regulate glia–neuron cholesterol transport, with neuronal compartments exhibiting enhanced efflux. GBM cells, unlike normal astrocytes, exhibit elevated LDLR expression, increased lipid uptake, and reduced endogenous LXR agonist levels, rendering them particularly sensitive to LXR activation (58). Additionally, epitranscriptomic control via m6A methylation reprograms cholesterol metabolism: YTHDF2-mediated degradation of LXRα mRNA represses ABCA1, ABCG1, and ApoE expression, promoting lipid accumulation and tumor progression (59, 60).
3.2 3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMGCR) and lipid rafts
Upregulation of HMGCR drives GBM proliferation and invasiveness through activation of the Hippo pathway effector TAZ and subsequent induction of CTGF. Conversely, pharmacologic or genetic inhibition of HMGCR limits tumor dissemination in vivo (60, 61). Statins, as HMGCR inhibitors, attenuate these malignant phenotypes, underscoring HMGCR as a potential therapeutic target (17). However, their efficacy in GBM remains limited, as tumor cells primarily depend on exogenous cholesterol uptake, unlike astrocytes, thereby reducing sensitivity to enzymatic blockade (62). The interaction between statins and temozolomide (TMZ) remains controversial, with reports indicating either reduced cytotoxicity or enhanced apoptotic activity (63, 64). These discrepancies appear to arise from disruptions in mevalonate pathway–regulated autophagy, rather than cholesterol depletion. Rab11 (a small GTPase) geranylgeranylation is essential for autophagosome formation; thus, inhibition of mevalonate flux impairs Rab11-mediated autophagic turnover and autophagosome–lysosome fusion, ultimately sensitizing GBM cells to TMZ-induced apoptosis (65). Lipid rafts serve as organizing centers for oncogenic signaling and apoptotic cascades (66, 67). In GBM, lipid rafts are critical for compartmentalization of death receptor 5 (DR5), which recruits FADD and caspase−8 to initiate extrinsic apoptosis and contributes to TMZ cytotoxicity (63, 68, 69). Cholesterol scaffolding within rafts facilitates DR5 clustering and DISC assembly. Elevated cholesterol enhances DR5 activation, and TMZ upregulates DR5 expression, suggesting that combining TMZ with strategies to enrich membrane cholesterol may potentiate raft-dependent apoptotic signaling (70).
4 SSP metabolism and key enzymes in glioma progression
4.1 Functions of serine
Cellular serine originates from extracellular uptake, glycine interconversion, or de novo synthesis via the serine synthesis pathway (SSP), a frequently dysregulated route in malignancies that promotes proliferation, therapy resistance, and poor prognosis (71). Transcriptional control of the SSP is coordinated by activating transcription factor 4 (ATF4), which upregulates key enzymes including PHGDH, PSAT1, PSPH, and SHMT (72, 73). Under serine limitation, ATF3 enhances this program by binding enhancer or promoter regions of SSP genes, amplifying adaptive responses (74). Transcription factor CP2 (TFCP2) further acts as an essential co-regulator; its depletion suppresses PHGDH expression and impairs glioma proliferation and tumorigenicity (75). Serine metabolism sustains tumors through multiple mechanisms: (i) supplying biosynthetic precursors, (ii) fueling mitochondrial folate-mediated one−carbon cycling to generate S−adenosylmethionine (SAM) for epigenetic methylation, and (iii) maintaining NADPH production via one−carbon metabolism to support redox balance and nucleotide synthesis (76). One−carbon units (methylene, methyl, and formyl groups) are shuttled by tetrahydrofolate (THF), linking serine catabolism to nucleotide biosynthesis and glutathione-dependent antioxidant systems (77). Serine serves as the major one−carbon donor: its conversion to glycine releases a methylene group into the folate cycle, driving SAM production and subsequent DNA/histone methylation (78, 79). In glioblastoma’s hypoxic, nutrient−poor niche, elevated serine and glycine levels are observed. Glutamine deprivation further upregulates PSAT1 and SHMT2, diverting serine flux into one−carbon metabolism as a stress−adaptive survival strategy (80). This metabolic flexibility underscores serine’s essential role in maintaining glioma viability under duress.
4.2 Key enzymes of the SSP and their association with GBM progression
4.2.1 PHGDH
PHGDH, a key rate-limiting enzyme in the serine synthesis pathway (SSP), is consistently upregulated in multiple malignancies including breast cancer, melanoma, and non−small cell lung cancer (81, 82). In glioma, PHGDH expression correlates with tumor grade, and its inhibition suppresses the transcription of proliferative and invasive mediators such as MMP−2, cyclin D1, VEGF, CHK2, and FOXM1, thereby limiting tumor growth and invasion in vitro and in vivo (83). In glioma cells with moderate-to−high endogenous PHGDH, silencing reduces the NADPH/NADP+ ratio, curbs proliferation, and increases susceptibility to hypoxia−induced apoptosis, whereas forced overexpression enhances hypoxia tolerance and tumorigenicity (84). Elevated PHGDH also contributes to therapy resistance and poor prognosis (85). For instance, PHGDH promotes mTORC1 activation and modulates rapamycin sensitivity during breast cancer lung metastasis (86). Multi−omics analyses reveal that ATF4−mediated transcriptional activation of PHGDH in glioblastoma endothelial cells redirects glycolytic flux toward nucleotide synthesis, fueling endothelial hyperproliferation. PHGDH inhibition alleviates tumor hypoxia, promotes cytotoxic T−lymphocyte infiltration, and augments CAR−T cell efficacy (87). Furthermore, PHGDH stabilizes FOXM1 via direct interaction, and its depletion prolongs survival in glioma xenografts, highlighting the PHGDH–FOXM1 axis as a promising therapeutic target (83).
4.2.2 PSAT1 and PSPH
PSAT1 and PSPH, which catalyze the sequential second and third reactions of the serine synthesis pathway (SSP), are frequently overexpressed in malignancies and promote oncogenic progression (88, 89). In triple−negative breast cancer, high PSAT1 expression correlates with enhanced aggressiveness, metastasis, and poor survival (90). Similarly, PSAT1 is upregulated in epithelial ovarian carcinoma, where its knockdown suppresses clonogenicity, induces G1 arrest, and promotes apoptosis (91). In gliomas, both enzymes are consistently elevated across histological grades compared to non−neoplastic brain tissue. Multiple Gene Expression Omnibus (GEO) datasets, qPCR, and immunoblot analyses confirm their overexpression in glioblastoma cell lines and glioma stem−like cells relative to normal astrocytes (6). Furthermore, in primary glioblastoma, PSAT1 and PSPH levels positively associate with phosphorylated AMPK (pT172) and HIF−1α activity (92). Patients with low PSAT1 or PSPH expression had a median overall survival of 20 weeks, whereas high expression predicted significantly shorter survival. These data underscore the AMPK–HIF−1α–SSP axis as a key driver of glioblastoma pathogenesis and a prognostic indicator (93).
4.2.3 SHMT
Serine hydroxymethyltransferase (SHMT) comprises cytosolic (SHMT1) and mitochondrial (SHMT2) isoforms, each catalyzing the reversible interconversion of serine and tetrahydrofolate (THF) to glycine and 5,10−methylenetetrahydrofolate in distinct subcellular compartments. While SHMT1 participates in cytosolic folate metabolism and pathway regulation (94), SHMT2 predominantly drives mitochondrial one−carbon flux through oxidative serine catabolism, a process tightly coupled to folate transport (95, 96). SHMT2 is frequently overexpressed in malignancies, including hepatocellular and lung carcinomas (97, 98), and elevated SHMT2 expression correlates with poor prognosis in gliomas, serving as an independent prognostic biomarker (99). In glioblastoma, SHMT2 and glycine decarboxylase (GLDC) are enriched within pseudopalisading cells surrounding necrotic regions, promoting survival under hypoxic conditions. SHMT2 further suppresses pyruvate kinase M2 (PKM2) activity and reduces oxygen consumption, enhancing persistence in ischemic niches. When GLDC activity is insufficient to catabolize accumulated glycine, toxic metabolites such as aminoacetone and methylglyoxal are produced, rendering SHMT2−overexpressing cells susceptible to GLDC inhibition (100). These observations establish SHMT2 as a central metabolic node facilitating glioma adaptation to nutrient and oxygen deprivation, highlighting its therapeutic relevance for targeting metabolic plasticity in the tumor microenvironment.
5 Emerging therapeutic strategies in GBM
Despite aggressive multimodal therapy—including surgical resection, radiotherapy, and temozolomide—GBM remains clinically intractable, necessitating precision-targeted strategies. Bevacizumab (BEV) is an anti-VEGF antibody for recurrent GBM to reduce angiogenesis and edema (101). Amplification or mutation of EGFR drives tumor proliferation and underlies poor prognosis, yet EGFR-targeted therapies have yielded limited efficacy due to intratumoral heterogeneity and adaptive resistance (102). Regorafenib, a multikinase inhibitor targeting VEGFR, PDGFR, and FGFR, has demonstrated clinical benefit in recurrent GBM and is under clinical evaluation (103). Additional actionable alterations include PTPRZ1–MET fusions responsive to capmatinib and BRAF V600E mutations sensitive to vemurafenib, particularly in pleomorphic xanthoastrocytoma (104). Nevertheless, EGFR-targeted therapies have yielded limited clinical success in GBM, largely due to intratumoral heterogeneity and adaptive resistance (105). Recent insights implicate lipid metabolic rewiring as a crucial modulator of receptor tyrosine kinase activity and drug response (106). ELOVL2-mediated enrichment of long-chain polyunsaturated phospholipids enhances membrane fluidity, promoting EGFR clustering and activation, thereby attenuating TKI efficacy (41, 107). In parallel, FABP7-driven lipid trafficking and COX-2–dependent prostaglandin synthesis amplify the oncogenic cascades, revealing a metabolic–signaling axis that may be therapeutically actionable. These findings support combined inhibition of EGFR and lipid metabolism to overcome resistance and enhance therapeutic durability (17, 108).
GBM exhibits marked metabolic plasticity, extending to serine metabolism. While many tumors rely on exogenous serine (109, 110), GBM adapts to deprivation by activating the serine synthesis pathway (SSP). Serine withdrawal suppresses pyruvate kinase M2 (PKM2), diverting glycolytic intermediates into SSP via ATF4- and G9A-mediated induction of PHGDH, PSAT1 and PSPH (111, 112). As the rate-limiting SSP enzyme, PHGDH is crucial for redox homeostasis and nucleotide synthesis. Concurrent PHGDH targeting and dietary serine/glycine restriction severely impair nucleotide and glutathione production, suppressing tumor growth (113, 114). Notably, neither glycine nor one-carbon donors alone restore proliferation, though combined supplementation partially rescues ATP and GTP levels. SSP dependence varies across GBM lines: LN-308 and LN-229 (PHGDH−low) are serine−dependent, whereas G55 (PHGDH−high) shows resistance. PHGDH inhibition by CBR-5884 under –SG conditions further suppress proliferation and exacerbates hypoxia−induced cytotoxicity (115). The selective PHGDH inhibitor NCT503 synergizes with temozolomide to induce apoptosis in chemoresistant, MGMT−expressing models (116). Regorafenib stabilizes PSAT1 and concurrently inhibits autophagic flux through PRKAA activation and RAB11A disruption; PSAT1 levels correlate with drug sensitivity (117). Beyond serine metabolism, targeting lipid biosynthetic enzymes represents an emerging therapeutic axis. Fatty acid synthase (FASN)—upregulated in high−grade gliomas—drives palmitate synthesis for membrane biogenesis and oncogenic signaling (118, 119); its inhibitor TVB-2640 shows preclinical efficacy. SCD1, which modulates fatty acid saturation and membrane fluidity, also supports glioma survival (32, 120). SCD1 inhibition increases oxidative susceptibility and may synergize with ferroptosis inducers or chemotherapy (121, 122). Collectively, FASN and SCD1 represent promising targets for combinatorial approaches aimed at disrupting GBM’s lipid−mediated adaptive capacity.
6 Conclusion
Glioblastoma exhibits profound metabolic plasticity, in which serine and lipid metabolic rewiring collectively sustains tumor proliferation, redox homeostasis, immune evasion, and resistance to therapy. The serine synthesis pathway, through PHGDH, PSAT1, and SHMT2, supports nucleotide and glutathione production while fueling one-carbon metabolism, SAM-dependent methylation, and NADPH generation. In parallel, aberrant lipid metabolism, including fatty acid elongation, desaturation, and cholesterol accumulation, drives glioma stemness, reshapes the immunosuppressive microenvironment, and modulates ferroptosis sensitivity. Importantly, serine-derived metabolites such as NADPH and SAM act as metabolic bridges linking amino acid and lipid biosynthesis, establishing a tightly coordinated metabolic–epigenetic network that enables glioma cells to adapt to hypoxia and nutrient deprivation.
This review underscores the clinical potential of targeting serine–lipid metabolic crosstalk in GBM. Inhibitors of SSP enzymes (PHGDH, SHMT2), fatty acid metabolism (FASN, SCD1), and cholesterol homeostasis (LXR agonists) have shown synergistic effects when combined with chemotherapy, ferroptosis inducers, or autophagy blockers. As spatial and single-cell multi-omics technologies evolve, uncovering metabolic heterogeneity across tumor subtypes and immune niches will be essential for refining metabolic vulnerabilities. By dissecting the convergent metabolic dependencies that sustain glioma aggressiveness, future therapeutic strategies may exploit these rewired circuits to overcome resistance and achieve durable clinical responses in GBM.
Author contributions
DJ: Writing – original draft. CW: Writing – original draft. YZ: Writing – original draft. YL: Writing – review & editing, Writing – original draft.
Funding
The author(s) declared that financial support was received for this work and/or its publication. This study was funded by Natural Science Foundation of Jilin Province (YDZJ202401398ZYTS), Special medical and health talents of Jilin Province (JLSWSRCZX2023-12), and National Key Research and Development Program of China (2023YFC2411602).
Conflict of interest
The author(s) declared that this work was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Generative AI statement
The author(s) declared that generative AI was not used in the creation of this manuscript.
Any alternative text (alt text) provided alongside figures in this article has been generated by Frontiers with the support of artificial intelligence and reasonable efforts have been made to ensure accuracy, including review by the authors wherever possible. If you identify any issues, please contact us.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
References
1. Force LM, Kocarnik JM, May ML, Bhangdia K, Crist A, Penberthy L, et al. The global, regional, and national burden of cancer, 1990-2023, with forecasts to 2050: a systematic analysis for the Global Burden of Disease Study 2023. Lancet. (2025) 406:1565–86. doi: 10.1016/S0140-6736(25)01635-6
2. Tetzlaff SK, Reyhan E, Layer N, Bengtson CP, Heuer A, Schroers J, et al. Characterizing and targeting glioblastoma neuron-tumor networks with retrograde tracing. Cell. (2025) 188:390–411.e336. doi: 10.1016/j.cell.2024.11.002
3. Rowland EC, D’Antuono M, Jermakowicz AM, and Ayad NG. Methionine cycle inhibition disrupts antioxidant metabolism and reduces glioblastoma cell survival. J Biol Chem. (2025) 301:108349. doi: 10.1016/j.jbc.2025.108349
4. Yang R, Zhang G, Meng Z, Wang L, Li Y, Li H, et al. Glutamate dehydrogenase 1-catalytic glutaminolysis feedback activates EGFR/PI3K/AKT pathway and reprograms glioblastoma metabolism. Neuro Oncol. (2025) 27:668–81. doi: 10.1093/neuonc/noae222
5. Hesse F, Low J, Cao J, Bulat F, Kreis F, Wright AJ, et al. Deuterium MRI of serine metabolism in mouse models of glioblastoma. Magn Reson Med. (2024) 92:1811–21. doi: 10.1002/mrm.30198
6. Yun HJ, Li M, Guo D, Jeon SM, Park SH, Lim JS, et al. AMPK-HIF-1α signaling enhances glucose-derived de novo serine biosynthesis to promote glioblastoma growth. J Exp Clin Cancer Res. (2023) 42:340. doi: 10.1186/s13046-023-02927-3
7. Zeng Y, Zhao L, Zeng K, Zhan Z, Zhan Z, Li S, et al. TRAF3 loss protects glioblastoma cells from lipid peroxidation and immune elimination via dysregulated lipid metabolism. J Clin Invest. (2025) 135:e178550. doi: 10.1172/JCI178550
8. Zhong Y, Geng F, Mazik L, Yin X, Becker AP, Mohammed S, et al. Combinatorial targeting of glutamine metabolism and lysosomal-based lipid metabolism effectively suppresses glioblastoma. Cell Rep Med. (2024) 5:101706. doi: 10.1016/j.xcrm.2024.101706
9. Liu X, Liu B, Wang J, Liu H, Wu J, Qi Y, et al. PHGDH activation fuels glioblastoma progression and radioresistance via serine synthesis pathway. J Exp Clin Cancer Res. (2025) 44:99. doi: 10.1186/s13046-025-03361-3
10. Nakamizo A, Miyamatsu Y, Hirose H, Amano T, Matsuo S, Fujiwara M, et al. Metabolic remodeling of pyrimidine synthesis pathway and serine synthesis pathway in human glioblastoma. Sci Rep. (2022) 12:16277. doi: 10.1038/s41598-022-20613-w
11. Pan S, Fan M, Liu Z, Li X, and Wang H. Serine, glycine and one−carbon metabolism in cancer (Review). Int J Oncol. (2021) 58:158–70. doi: 10.3892/ijo.2020.5158
12. Lee H, Kim D, and Youn B. Targeting oncogenic rewiring of lipid metabolism for glioblastoma treatment. Int J Mol Sci. (2022) 23:13818. doi: 10.3390/ijms232213818
13. Liu H and Liu Y. Recent progress in serine metabolism reprogramming in tumors and strategies for serine deprivation. Front Oncol. (2025) 15:1669565. doi: 10.3389/fonc.2025.1669565
14. Reina-Campos M, Diaz-Meco MT, and Moscat J. The complexity of the serine glycine one-carbon pathway in cancer. J Cell Biol. (2020) 219:e201907022. doi: 10.1083/jcb.201907022
15. Lyu H, Bao S, Cai L, Wang M, Liu Y, Sun Y, et al. The role and research progress of serine metabolism in tumor cells. Front Oncol. (2025) 15:1509662. doi: 10.3389/fonc.2025.1509662
16. Petrova B, Maynard AG, Wang P, and Kanarek N. Regulatory mechanisms of one-carbon metabolism enzymes. J Biol Chem. (2023) 299:105457. doi: 10.1016/j.jbc.2023.105457
17. Lu L, Zhang Y, Yang Y, Jin M, Ma A, Wang X, et al. Lipid metabolism: the potential therapeutic targets in glioblastoma. Cell Death Discov. (2025) 11:107. doi: 10.1038/s41420-025-02390-3
18. Chandel NS. Lipid metabolism. Cold Spring Harb Perspect Biol. (2021) 13:a040576. doi: 10.1101/cshperspect.a040576
19. de Carvalho C and Caramujo MJ. The various roles of fatty acids. Molecules. (2018) 23:2583. doi: 10.3390/molecules23102583
20. Balijepalli P, Sitton CC, and Meier KE. Lysophosphatidic acid signaling in cancer cells: what makes LPA so special? Cells. (2021) 10:2059. doi: 10.3390/cells10082059
21. Nadhan R, Nath K, Basu S, Isidoro C, Song YS, and Dhanasekaran DN. Decoding lysophosphatidic acid signaling in physiology and disease: mapping the multimodal and multinodal signaling networks. Signal Transduct Target Ther. (2025) 10:337. doi: 10.1038/s41392-025-02423-4
22. Miska J and Chandel NS. Targeting fatty acid metabolism in glioblastoma. J Clin Invest. (2023), 133:e163448. doi: 10.1172/JCI163448
23. Hawly J, Murcar MG, Schcolnik-Cabrera A, and Issa ME. Glioblastoma stem cell metabolism and immunity. Cancer Metastasis Rev. (2024) 43:1015–35. doi: 10.1007/s10555-024-10183-w
24. Sloan AR, Silver DJ, Kint S, Gallo M, and Lathia JD. Cancer stem cell hypothesis 2.0 in glioblastoma: Where are we now and where are we going? Neuro Oncol. (2024) 26:785–95. doi: 10.1093/neuonc/noae011
25. Yin J, Kim SS, Choi E, Oh YT, Lin W, Kim TH, et al. et al: ARS2/MAGL signaling in glioblastoma stem cells promotes self-renewal and M2-like polarization of tumor-associated macrophages. Nat Commun. (2020) 11:2978. doi: 10.1038/s41467-020-16789-2
26. Zhao W, Zhang Z, Xie M, Ding F, Zheng X, Sun S, et al. Exploring tumor-associated macrophages in glioblastoma: from diversity to therapy. NPJ Precis Oncol. (2025) 9:126. doi: 10.1038/s41698-025-00920-x
27. Zhang Y, Xu X, Li S, Liao C, Yang X, and Zhang W. The role of immune- and lipid metabolism-related genes in macrophage polarization and prognosis of glioblastoma. Front Oncol. (2025) 15:1660754. doi: 10.3389/fonc.2025.1660754
28. Li X, Hu J, Zheng W, Fan Z, Chi H, Li H, et al. CircMAN1A2 levels determine GBM susceptibility to TMZ in a pathway involving TEP1- and KEAP1-mediated NRF2 degradation leading to ferroptosis. CNS Neurosci Ther. (2025) 31:e70489. doi: 10.1111/cns.70489
29. Kang S, Ughetta ME, Zhang JY, Marallano VJ, Sattiraju A, Hannah T, et al. et al: Glioblastoma shift from bulk to infiltrative growth is guided by plexin-B2-mediated microglia alignment in invasive niches. Nat Cancer. (2025) 6:1505–23. doi: 10.1038/s43018-025-00985-4
30. Tsai YL, Chen Y, Chen YC, and Tsai WC. KDELC2 upregulates glioblastoma angiogenesis via reactive oxygen species activation and tumor-associated macrophage proliferation. Antioxidants (Basel). (2023), 12:923. doi: 10.3390/antiox12040923
31. Liang H, Yang Q, Zhong B, Li D, Wu F, Zhang J, et al. IL-1β(+) tumor-associated macrophages accelerate glioblastoma progression by amplifying the PGE2-EP4 signaling. J Neuroinflamm. (2025) 22:233. doi: 10.1186/s12974-025-03551-y
32. Morais CM, Cardoso AM, Araújo ARD, Reis A, Domingues P, Domingues MRM, et al. Stearoyl coA desaturase-1 silencing in glioblastoma cells: phospholipid remodeling and cytotoxicity enhanced upon autophagy inhibition. Int J Mol Sci. (2022) 23:13014. doi: 10.3390/ijms232113014
33. Kamphorst JJ, Cross JR, Fan J, de StanChina E, Mathew R, White EP, et al. Hypoxic and Ras-transformed cells support growth by scavenging unsaturated fatty acids from lysophospholipids. Proc Natl Acad Sci U.S.A. (2013) 110:8882–7. doi: 10.1073/pnas.1307237110
34. Pan YH, Chen J, Sun C, Ma JF, and Li X. Effect of Ras-guanine nucleotide release factor 1-mediated H-Ras/ERK signaling pathway on glioma. Brain Res. (2021) 1754:147247. doi: 10.1016/j.brainres.2020.147247
35. Gerstner JR, Bremer QZ, Vander Heyden WM, Lavaute TM, Yin JC, and Landry CF. Brain fatty acid binding protein (Fabp7) is diurnally regulated in astrocytes and hippocampal granule cell precursors in adult rodent brain. PloS One. (2008) 3:e1631. doi: 10.1371/journal.pone.0001631
36. Storch J and Corsico B. The multifunctional family of mammalian fatty acid-binding proteins. Annu Rev Nutr. (2023) 43:25–54. doi: 10.1146/annurev-nutr-062220-112240
37. Umaru BA, Kagawa Y, Ohsaki Y, Pan Y, Chen CT, Chen DK, et al. et al: Oleic acid-bound FABP7 drives glioma cell proliferation through regulation of nuclear lipid droplet formation. FEBS J. (2023) 290:1798–821. doi: 10.1111/febs.16672
38. De Rosa A, Pellegatta S, Rossi M, Tunici P, Magnoni L, Speranza MC, et al. A radial glia gene marker, fatty acid binding protein 7 (FABP7), is involved in proliferation and invasion of glioblastoma cells. PloS One. (2012) 7:e52113. doi: 10.1371/journal.pone.0052113
39. Mita R, Beaulieu MJ, Field C, and Godbout R. Brain fatty acid-binding protein and omega-3/omega-6 fatty acids: mechanistic insight into Malignant glioma cell migration. J Biol Chem. (2010) 285:37005–15. doi: 10.1074/jbc.M110.170076
40. Kagawa Y, Umaru BA, Shima H, Ito R, Zama R, Islam A, et al. et al: FABP7 regulates acetyl-coA metabolism through the interaction with ACLY in the nucleus of astrocytes. Mol Neurobiol. (2020) 57:4891–910. doi: 10.1007/s12035-020-02057-3
41. Gimple RC, Kidwell RL, Kim LJY, Sun T, Gromovsky AD, Wu Q, et al. et al: glioma stem cell-specific superenhancer promotes polyunsaturated fatty-acid synthesis to support EGFR signaling. Cancer Discov. (2019) 9:1248–67. doi: 10.1158/2159-8290.CD-19-0061
42. Zhou Y, Zeng L, Cai L, Zheng W, Liu X, Xiao Y, et al. et al: Cellular senescence-associated gene IFI16 promotes HMOX1-dependent evasion of ferroptosis and radioresistance in glioblastoma. Nat Commun. (2025) 16:1212. doi: 10.1038/s41467-025-56456-y
43. Wang Z, Ding Y, Wang X, Lu S, Wang C, He C, et al. Pseudolaric acid B triggers ferroptosis in glioma cells via activation of Nox4 and inhibition of xCT. Cancer Lett. (2018) 428:21–33. doi: 10.1016/j.canlet.2018.04.021
44. Sehm T, Rauh M, Wiendieck K, Buchfelder M, Eyüpoglu IY, and Savaskan NE. Temozolomide toxicity operates in a xCT/SLC7a11 dependent manner and is fostered by ferroptosis. Oncotarget. (2016) 7:74630–47. doi: 10.18632/oncotarget.11858
45. Jia B, Li J, Song Y, and Luo C. ACSL4-mediated ferroptosis and its potential role in central nervous system diseases and injuries. Int J Mol Sci. (2023) 24:10021. doi: 10.3390/ijms241210021
46. Cheng J, Fan YQ, Liu BH, Zhou H, Wang JM, and Chen QX. ACSL4 suppresses glioma cells proliferation via activating ferroptosis. Oncol Rep. (2020) 43:147–58. doi: 10.3892/or.2019.7419
47. Kennewick KT and Bensinger SJ. Decoding the crosstalk between mevalonate metabolism and T cell function. Immunol Rev. (2023) 317:71–94. doi: 10.1111/imr.13200
48. Cui D, Yu X, Guan Q, Shen Y, Liao J, Liu Y, et al. Cholesterol metabolism: molecular mechanisms, biological functions, diseases, and therapeutic targets. Mol BioMed. (2025) 6:72. doi: 10.1186/s43556-025-00321-3
49. Villa GR, Hulce JJ, Zanca C, Bi J, Ikegami S, Cahill GL, et al. et al: an LXR-cholesterol axis creates a metabolic co-dependency for brain cancers. Cancer Cell. (2016) 30:683–93. doi: 10.1016/j.ccell.2016.09.008
50. Jacobo-Albavera L, Domínguez-Pérez M, Medina-Leyte DJ, González-Garrido A, and Villarreal-Molina T. The role of the ATP-binding cassette A1 (ABCA1) in human disease. Int J Mol Sci. (2021) 22:1593. doi: 10.3390/ijms22041593
51. Wen YA, Xiong X, Zaytseva YY, Napier DL, Vallee E, Li AT, et al. Downregulation of SREBP inhibits tumor growth and initiation by altering cellular metabolism in colon cancer. Cell Death Dis. (2018) 9:265. doi: 10.1038/s41419-018-0330-6
52. Xue L, Qi H, Zhang H, Ding L, Huang Q, Zhao D, et al. Targeting SREBP-2-regulated mevalonate metabolism for cancer therapy. Front Oncol. (2020) 10:1510. doi: 10.3389/fonc.2020.01510
53. Ingallina E, Sorrentino G, Bertolio R, Lisek K, Zannini A, Azzolin L, et al. et al: Mechanical cues control mutant p53 stability through a mevalonate-RhoA axis. Nat Cell Biol. (2018) 20:28–35. doi: 10.1038/s41556-017-0009-8
54. Parrales A, Thoenen E, and Iwakuma T. The interplay between mutant p53 and the mevalonate pathway. Cell Death Differ. (2018) 25:460–70. doi: 10.1038/s41418-017-0026-y
55. Lakhter AJ, Hamilton J, Konger RL, Brustovetsky N, Broxmeyer HE, and Naidu SR. Glucose-independent acetate metabolism promotes melanoma cell survival and tumor growth. J Biol Chem. (2016) 291:21869–79. doi: 10.1074/jbc.M115.712166
56. Li D, Li S, Xue AZ, Smith Callahan LA, and Liu Y. Expression of SREBP2 and cholesterol metabolism related genes in TCGA glioma cohorts. Med (Baltimore). (2020) 99:e18815. doi: 10.1097/MD.0000000000018815
57. Fang R, Chen X, Zhang S, Shi H, Ye Y, Shi H, et al. et al: EGFR/SRC/ERK-stabilized YTHDF2 promotes cholesterol dysregulation and invasive growth of glioblastoma. Nat Commun. (2021) 12:177. doi: 10.1038/s41467-020-20379-7
58. Yang R, Zhao Y, Gu Y, Yang Y, Gao X, Yuan Y, et al. et al: Isocitrate dehydrogenase 1 mutation enhances 24(S)-hydroxycholesterol production and alters cholesterol homeostasis in glioma. Oncogene. (2020) 39:6340–53. doi: 10.1038/s41388-020-01439-0
59. Zhang S. Mechanism of N(6)-methyladenosine modification and its emerging role in cancer. Pharmacol Ther. (2018) 189:173–83. doi: 10.1016/j.pharmthera.2018.04.011
60. Qiu Z, Yuan W, Chen T, Zhou C, Liu C, Huang Y, et al. HMGCR positively regulated the growth and migration of glioblastoma cells. Gene. (2016) 576:22–7. doi: 10.1016/j.gene.2015.09.067
61. Yang R, Wu Y, Zou J, Zhou J, Wang M, Hao X, et al. The Hippo transducer TAZ promotes cell proliferation and tumor formation of glioblastoma cells through EGFR pathway. Oncotarget. (2016) 7:36255–65. doi: 10.18632/oncotarget.9199
62. Pirmoradi L, Seyfizadeh N, Ghavami S, Zeki AA, and Shojaei S. Targeting cholesterol metabolism in glioblastoma: a new therapeutic approach in cancer therapy. J Investig Med. (2019) 67:715–9. doi: 10.1136/jim-2018-000962
63. Yamamoto Y, Tomiyama A, Sasaki N, Yamaguchi H, Shirakihara T, Nakashima K, et al. et al: Intracellular cholesterol level regulates sensitivity of glioblastoma cells against temozolomide-induced cell death by modulation of caspase-8 activation via death receptor 5-accumulation and activation in the plasma membrane lipid raft. Biochem Biophys Res Commun. (2018) 495:1292–9. doi: 10.1016/j.bbrc.2017.11.113
64. Shojaei S, Alizadeh J, Thliveris J, Koleini N, Kardami E, Hatch G, et al. Inhibition of autophagy by mevalonate pathway inhibitors, a new therapeutic approach to sensitize glioblastoma cells to temozolomide induced apoptosis. The FASEB Journal. (2018) 32:533.541–533.541. doi: 10.1096/fasebj.2018.32.1_supplement.533.41
65. Miettinen TP and Björklund M. Mevalonate pathway regulates cell size homeostasis and proteostasis through autophagy. Cell Rep. (2015) 13:2610–20. doi: 10.1016/j.celrep.2015.11.045
66. Hryniewicz-Jankowska A, Augoff K, Biernatowska A, Podkalicka J, and Sikorski AF. Membrane rafts as a novel target in cancer therapy. Biochim Biophys Acta. (2014) 1845:155–65. doi: 10.1016/j.bbcan.2014.01.006
67. Vona R, Iessi E, and Matarrese P. Role of cholesterol and lipid rafts in cancer signaling: A promising therapeutic opportunity? Front Cell Dev Biol. (2021) 9:622908. doi: 10.3389/fcell.2021.622908
68. Guo X, Zhou S, Yang Z, Li ZA, Hu W, Dai L, et al. Cholesterol metabolism and its implication in glioblastoma therapy. J Cancer. (2022) 13:1745–57. doi: 10.7150/jca.63609
69. Bellail AC, Tse MC, Song JH, Phuphanich S, Olson JJ, Sun SY, et al. DR5-mediated DISC controls caspase-8 cleavage and initiation of apoptosis in human glioblastomas. J Cell Mol Med. (2010) 14:1303–17. doi: 10.1111/j.1582-4934.2009.00777.x
70. Yamamoto Y, Sasaki N, Kumagai K, Takeuchi S, Toyooka T, Otani N, et al. et al: involvement of intracellular cholesterol in temozolomide-induced glioblastoma cell death. Neurol Med Chir (Tokyo). (2018) 58:296–302. doi: 10.2176/nmc.ra.2018-0040
71. Wortel IMN, van der Meer LT, Kilberg MS, and van Leeuwen FN. Surviving stress: modulation of ATF4-mediated stress responses in normal and Malignant cells. Trends Endocrinol Metab. (2017) 28:794–806. doi: 10.1016/j.tem.2017.07.003
72. Van Nyen T, Planque M, van Wagensveld L, Duarte JAG, Zaal EA, Talebi A, et al. et al: Serine metabolism remodeling after platinum-based chemotherapy identifies vulnerabilities in a subgroup of resistant ovarian cancers. Nat Commun. (2022) 13:4578. doi: 10.1038/s41467-022-32272-6
73. Li AM and Ye J. The PHGDH enigma: Do cancer cells only need serine or also a redox modulator? Cancer Lett. (2020) 476:97–105. doi: 10.1016/j.canlet.2020.01.036
74. Li X, Gracilla D, Cai L, Zhang M, Yu X, Chen X, et al. ATF3 promotes the serine synthesis pathway and tumor growth under dietary serine restriction. Cell Rep. (2021) 36:109706. doi: 10.1016/j.celrep.2021.109706
75. Kotarba G, Krzywinska E, Grabowska AI, Taracha A, and Wilanowski T. TFCP2/TFCP2L1/UBP1 transcription factors in cancer. Cancer Lett. (2018) 420:72–9. doi: 10.1016/j.canlet.2018.01.078
76. Luo X, Ge J, Liu J, Liu Z, Bi C, and Lan S. TFCP2, a binding protein of ATF3, promotes the progression of glioma by activating the synthesis of serine. Exp Cell Res. (2022) 416:113136. doi: 10.1016/j.yexcr.2022.113136
77. Locasale JW. Serine, glycine and one-carbon units: cancer metabolism in full circle. Nat Rev Cancer. (2013) 13:572–83. doi: 10.1038/nrc3557
78. Newman AC and Maddocks ODK. One-carbon metabolism in cancer. Br J Cancer. (2017) 116:1499–504. doi: 10.1038/bjc.2017.118
79. Zhou X, Tian C, Cao Y, Zhao M, and Wang K. The role of serine metabolism in lung cancer: From oncogenesis to tumor treatment. Front Genet. (2022) 13:1084609. doi: 10.3389/fgene.2022.1084609
80. Tanaka K, Sasayama T, Nagashima H, Irino Y, Takahashi M, Izumi Y, et al. et al: Glioma cells require one-carbon metabolism to survive glutamine starvation. Acta Neuropathol Commun. (2021) 9:16. doi: 10.1186/s40478-020-01114-1
81. DeNicola GM, Chen PH, Mullarky E, Sudderth JA, Hu Z, Wu D, et al. et al: NRF2 regulates serine biosynthesis in non-small cell lung cancer. Nat Genet. (2015) 47:1475–81. doi: 10.1038/ng.3421
82. Possemato R, Marks KM, Shaul YD, Pacold ME, Kim D, Birsoy K, et al. et al: Functional genomics reveal that the serine synthesis pathway is essential in breast cancer. Nature. (2011) 476:346–50. doi: 10.1038/nature10350
83. Liu J, Guo S, Li Q, Yang L, Xia Z, Zhang L, et al. Phosphoglycerate dehydrogenase induces glioma cells proliferation and invasion by stabilizing forkhead box M1. J Neurooncol. (2013) 111:245–55. doi: 10.1007/s11060-012-1018-x
84. Engel AL, Lorenz NI, Klann K, Münch C, Depner C, Steinbach JP, et al. Serine-dependent redox homeostasis regulates glioblastoma cell survival. Br J Cancer. (2020) 122:1391–8. doi: 10.1038/s41416-020-0794-x
85. Ma C, Zheng K, Jiang K, Zhao Q, Sha N, Wang W, et al. The alternative activity of nuclear PHGDH contributes to tumour growth under nutrient stress. Nat Metab. (2021) 3:1357–71. doi: 10.1038/s42255-021-00456-x
86. Rinaldi G, Pranzini E, Van Elsen J, Broekaert D, Funk CM, Planque M, et al. et al: In Vivo Evidence for Serine Biosynthesis-Defined Sensitivity of Lung Metastasis, but Not of Primary Breast Tumors, to mTORC1 Inhibition. Mol Cell. (2021) 81:386–397.e387. doi: 10.1016/j.molcel.2020.11.027
87. Zhang D, Li AM, Hu G, Huang M, Yang F, Zhang L, et al. et al: PHGDH-mediated endothelial metabolism drives glioblastoma resistance to chimeric antigen receptor T cell immunotherapy. Cell Metab. (2023) 35:517–534.e518. doi: 10.1016/j.cmet.2023.01.010
88. Yang Y, Wu J, Cai J, He Z, Yuan J, Zhu X, et al. PSAT1 regulates cyclin D1 degradation and sustains proliferation of non-small cell lung cancer cells. Int J Cancer. (2015) 136:E39–50. doi: 10.1002/ijc.29150
89. Jovov B, Araujo-Perez F, Sigel CS, Stratford JK, McCoy AN, Yeh JJ, et al. Differential gene expression between African American and European American colorectal cancer patients. PloS One. (2012) 7:e30168. doi: 10.1371/journal.pone.0030168
90. Metcalf S, Dougherty S, Kruer T, Hasan N, Biyik-Sit R, Reynolds L, et al. Selective loss of phosphoserine aminotransferase 1 (PSAT1) suppresses migration, invasion, and experimental metastasis in triple negative breast cancer. Clin Exp Metastasis. (2020) 37:187–97. doi: 10.1007/s10585-019-10000-7
91. Zhang Y, Li J, Dong X, Meng D, Zhi X, Yuan L, et al. PSAT1 regulated oxidation-reduction balance affects the growth and prognosis of epithelial ovarian cancer. Onco Targets Ther. (2020) 13:5443–53. doi: 10.2147/OTT.S250066
92. Chhipa RR, Fan Q, Anderson J, Muraleedharan R, Huang Y, Ciraolo G, et al. et al: AMP kinase promotes glioblastoma bioenergetics and tumour growth. Nat Cell Biol. (2018) 20:823–35. doi: 10.1038/s41556-018-0126-z
93. Feng M, Cui H, Tu W, Li L, Gao Y, Chen L, et al. An integrated pan-cancer analysis of PSAT1: A potential biomarker for survival and immunotherapy. Front Genet. (2022) 13:975381. doi: 10.3389/fgene.2022.975381
94. Giardina G, Paone A, Tramonti A, Lucchi R, Marani M, Magnifico MC, et al. et al: The catalytic activity of serine hydroxymethyltransferase is essential for de novo nuclear dTMP synthesis in lung cancer cells. FEBS J. (2018) 285:3238–53. doi: 10.1111/febs.14610
95. Zhu S, Liu Y, Chen H, Zhu X, Liu X, Xu K, et al. Mechanism and therapeutic progress of one-carbon metabolic key enzyme: serine hydroxymethyltransferase 2 in cancer. Clin Med Insights Oncol. (2025) 19:11795549251331755. doi: 10.1177/11795549251331755
96. Dekhne AS, Hou Z, Gangjee A, and Matherly LH. Therapeutic targeting of mitochondrial one-carbon metabolism in cancer. Mol Cancer Ther. (2020) 19:2245–55. doi: 10.1158/1535-7163.MCT-20-0423
97. Luo L, Zheng Y, Lin Z, Li X, Li X, Li M, et al. Identification of SHMT2 as a potential prognostic biomarker and correlating with immune infiltrates in lung adenocarcinoma. J Immunol Res. (2021) 2021:6647122. doi: 10.1155/2021/6647122
98. Woo CC, Chen WC, Teo XQ, Radda GK, and Lee PT. Downregulating serine hydroxymethyltransferase 2 (SHMT2) suppresses tumorigenesis in human hepatocellular carcinoma. Oncotarget. (2016) 7:53005–17. doi: 10.18632/oncotarget.10415
99. Wang B, Wang W, Zhu Z, Zhang X, Tang F, Wang D, et al. Mitochondrial serine hydroxymethyltransferase 2 is a potential diagnostic and prognostic biomarker for human glioma. Clin Neurol Neurosurg. (2017) 154:28–33. doi: 10.1016/j.clineuro.2017.01.005
100. Kim D, Fiske BP, Birsoy K, Freinkman E, Kami K, Possemato RL, et al. et al: SHMT2 drives glioma cell survival in ischaemia but imposes a dependence on glycine clearance. Nature. (2015) 520:363–7. doi: 10.1038/nature14363
101. Narita Y. Bevacizumab for glioblastoma. Ther Clin Risk Manag. (2015) 11:1759–65. doi: 10.2147/TCRM.S58289
102. Ge M, Zhu Y, Wei M, Piao H, and He M. Improving the efficacy of anti-EGFR drugs in GBM: Where we are going? Biochim Biophys Acta Rev Cancer. (2023) 1878:188996. doi: 10.1016/j.bbcan.2023.188996
103. Lombardi G, Caccese M, Padovan M, Cerretti G, Pintacuda G, Manara R, et al. Regorafenib in recurrent glioblastoma patients: A large and monocentric real-life study. Cancers (Basel). (2021) 13:4731. doi: 10.3390/cancers13184731
104. Maddocks OD, Berkers CR, Mason SM, Zheng L, Blyth K, Gottlieb E, et al. Serine starvation induces stress and p53-dependent metabolic remodelling in cancer cells. Nature. (2013) 493:542–6. doi: 10.1038/nature11743
105. Blomquist MR, Noviello TMR, Sereduk C, Grief D, Caruso FP, Sharma R, et al. et al: Glioblastoma resistance to EGFR antibody-drug conjugate is driven by transcriptional reprogramming and TEK-induced EGFR suppression. J Transl Med. (2025) 23:1153. doi: 10.1186/s12967-025-07216-5
106. D’Aprile S, Denaro S, Gervasi A, Vicario N, and Parenti R. Targeting metabolic reprogramming in glioblastoma as a new strategy to overcome therapy resistance. Front Cell Dev Biol. (2025) 13:1535073. doi: 10.3389/fcell.2025.1535073
107. Korbecki J, Bosiacki M, Gutowska I, Chlubek D, and Baranowska-Bosiacka I. Biosynthesis and significance of fatty acids, glycerophospholipids, and triacylglycerol in the processes of glioblastoma tumorigenesis. Cancers (Basel). (2023), 15:2183. doi: 10.3390/cancers15072183
108. Shen CJ, Chen HC, Lin CL, Thakur A, Onuku R, Chen IC, et al. et al: contribution of prostaglandin E2-induced neuronal excitation to drug resistance in glioblastoma countered by a novel blood-brain barrier crossing celecoxib derivative. Adv Sci (Weinh). (2025) 12:e06336. doi: 10.1002/advs.202506336
109. Labuschagne CF, van den Broek NJ, Mackay GM, Vousden KH, and Maddocks OD. Serine, but not glycine, supports one-carbon metabolism and proliferation of cancer cells. Cell Rep. (2014) 7:1248–58. doi: 10.1016/j.celrep.2014.04.045
110. Chaneton B, Hillmann P, Zheng L, Martin ACL, Maddocks ODK, Chokkathukalam A, et al. et al: Serine is a natural ligand and allosteric activator of pyruvate kinase M2. Nature. (2012) 491:458–62. doi: 10.1038/nature11540
111. Ye J, Mancuso A, Tong X, Ward PS, Fan J, Rabinowitz JD, et al. Pyruvate kinase M2 promotes de novo serine synthesis to sustain mTORC1 activity and cell proliferation. Proc Natl Acad Sci U.S.A. (2012) 109:6904–9. doi: 10.1073/pnas.1204176109
112. Ding J, Li T, Wang X, Zhao E, Choi JH, Yang L, et al. et al: The histone H3 methyltransferase G9A epigenetically activates the serine-glycine synthesis pathway to sustain cancer cell survival and proliferation. Cell Metab. (2013) 18:896–907. doi: 10.1016/j.cmet.2013.11.004
113. Montrose DC, Saha S, Foronda M, McNally EM, Chen J, Zhou XK, et al. et al: exogenous and endogenous sources of serine contribute to colon cancer metabolism, growth, and resistance to 5-fluorouracil. Cancer Res. (2021) 81:2275–88. doi: 10.1158/0008-5472.CAN-20-1541
114. Tajan M, Hennequart M, Cheung EC, Zani F, Hock AK, Legrave N, et al. et al: Serine synthesis pathway inhibition cooperates with dietary serine and glycine limitation for cancer therapy. Nat Commun. (2021) 12:366. doi: 10.1038/s41467-020-20223-y
115. Mullarky E, Lucki NC, Beheshti Zavareh R, Anglin JL, Gomes AP, Nicolay BN, et al. et al: Identification of a small molecule inhibitor of 3-phosphoglycerate dehydrogenase to target serine biosynthesis in cancers. Proc Natl Acad Sci U.S.A. (2016) 113:1778–83. doi: 10.1073/pnas.1521548113
116. Jin L, Kiang KM, Cheng SY, and Leung GK. Pharmacological inhibition of serine synthesis enhances temozolomide efficacy by decreasing O(6)-methylguanine DNA methyltransferase (MGMT) expression and reactive oxygen species (ROS)-mediated DNA damage in glioblastoma. Lab Invest. (2022) 102:194–203. doi: 10.1038/s41374-021-00666-7
117. Jiang J, Zhang L, Chen H, Lei Y, Zhang T, Wang Y, et al. et al: Regorafenib induces lethal autophagy arrest by stabilizing PSAT1 in glioblastoma. Autophagy. (2020) 16:106–22. doi: 10.1080/15548627.2019.1598752
118. Wang N, Yuan Y, Hu T, Xu H, and Piao H. Metabolism: an important player in glioma survival and development. Discov Oncol. (2024) 15:577. doi: 10.1007/s12672-024-01402-5
119. Huang L, Zhang M, and Xiao Y. Fatty acid synthase in chemoresistance: mechanisms and therapeutic opportunities. Front Pharmacol. (2025) 16:1674752. doi: 10.3389/fphar.2025.1674752
120. Kelly W, Diaz Duque AE, Michalek J, Konkel B, Caflisch L, Chen Y, et al. : phase II investigation of TVB-2640 (Denifanstat) with bevacizumab in patients with first relapse high-grade astrocytoma. Clin Cancer Res. (2023) 29:2419–25. doi: 10.1158/1078-0432.CCR-22-2807
121. Sun H, Zhang J, Qi H, Jiang D, Hu C, Mao C, et al. Ioning out glioblastoma: ferroptosis mechanisms and therapeutic frontiers. Cell Death Discov. (2025) 11:407. doi: 10.1038/s41420-025-02711-6
Keywords: fatty acid metabolism, glioblastoma, liver X receptors, metabolic intervention, phosphoglycerate dehydrogenase, serine, tumor microenvironment
Citation: Jiang D, Wang C, Zhao Y and Li Y (2026) Metabolic remodeling and immune evasion in glioblastoma: a focus on serine and lipid networks. Front. Oncol. 16:1676560. doi: 10.3389/fonc.2026.1676560
Received: 31 July 2025; Accepted: 16 January 2026; Revised: 08 January 2026;
Published: 03 February 2026.
Edited by:
Maria Letizia Taddei, University of Florence, ItalyReviewed by:
Hayk Mnatsakanyan, Massachusetts General Hospital and Harvard Medical School, United StatesCopyright © 2026 Jiang, Wang, Zhao and Li. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Yunqian Li, eXVucWlhbkBqbHUuZWR1LmNu